Skip to content
HowShorted

Intra-Cellular Therapies Inc. short interest in 2020

In 2020, Intra-Cellular Therapies Inc.'s disclosed short interest ran from 11.83% of shares outstanding on 15 Jan 2020 to 9.45% on 31 Dec 2020, a change of -2.38 percentage points. The year's high was 11.83% on 15 Jan 2020 and its low 7.20% on 13 Nov 2020, averaging 8.16% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.14 days on 31 Aug 2020. Full history: Intra-Cellular Therapies Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Intra-Cellular Therapies Inc. in 2020

2020 in figures

Start of year
11.83% (15 Jan 2020)
End of year
9.45% (31 Dec 2020)
Change
-2.38 pp
High
11.83% (15 Jan 2020)
Low
7.20% (13 Nov 2020)
Average
8.16%
Highest days to cover
13.14 (31 Aug 2020)
SEC filings marked
9

Every report in 2020

Intra-Cellular Therapies Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202011.83%1.99results (8-K)
31 Jan 20207.88%3.90
14 Feb 20208.05%5.93
28 Feb 20207.22%4.32
13 Mar 20207.36%6.0310-K filed, results (8-K)
31 Mar 20207.66%5.03
15 Apr 20207.66%9.20
30 Apr 20208.15%10.29
15 May 20208.28%6.5010-Q filed, results (8-K)
29 May 20207.44%6.34
15 Jun 20207.45%5.89
30 Jun 20208.03%4.95
15 Jul 20207.73%7.09
31 Jul 20207.34%8.89
14 Aug 20207.36%7.1110-Q filed, results (8-K)
31 Aug 20207.94%13.14
15 Sep 202010.01%1.00
30 Sep 20208.72%4.92
15 Oct 20208.76%7.25
30 Oct 20208.13%9.12
13 Nov 20207.20%7.0110-Q filed, results (8-K)
30 Nov 20207.85%9.70
15 Dec 20208.46%11.23
31 Dec 20209.45%9.69

See also: Intra-Cellular Therapies Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.